UK Markets closed

Addex Therapeutics Ltd (ADDXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.99000.0000 (0.00%)
At close: 09:31AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.9900
Open0.9900
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.9900 - 0.9900
52-week range0.9900 - 0.9900
Volume100
Avg. volume0
Market cap32.099M
Beta (5Y monthly)1.80
PE ratio (TTM)N/A
EPS (TTM)-0.5280
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est28.00
  • Globe Newswire

    Addex Provides Corporate Update and Financial Guidance

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guidance. “We ended 2022 with CHF7.0 million of cash and expect to be able to finance our operations until Q3 2023. We continue to focus on entering into collaborative arra

  • Globe Newswire

    Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

    Addex to receive USD 1 million in additional research fundingCollaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 8, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the research term of its collaboration agreement with Indivior PLC (LON: INDV) for the discovery of novel o

  • Globe Newswire

    Addex Reports Q3 2022 Financial Results and Provides Corporate Update

    CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its Q3 financial results for the period ended September 30, 2022 and provided a corporate upd